دورية أكاديمية
Sodium/Glucose Cotransporter 2 Inhibitors and Magnesium Homeostasis: A Review.
| العنوان: | Sodium/Glucose Cotransporter 2 Inhibitors and Magnesium Homeostasis: A Review. |
|---|---|
| المؤلفون: | Shah CV; Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, Florida. Electronic address: shahc@ufl.edu., Sparks MA; Division of Nephrology and Department of Medicine, Duke University, and Durham VA Health Care System, Durham, North Carolina., Lee CT; Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Kaohsiung Municipal Feng-Shan Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. |
| المصدر: | American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2024 May; Vol. 83 (5), pp. 648-658. Date of Electronic Publication: 2024 Feb 17. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8110075 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-6838 (Electronic) Linking ISSN: 02726386 NLM ISO Abbreviation: Am J Kidney Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Philadelphia Pa : W.B. Saunders Original Publication: New York, N.Y. : Grune & Stratton, c1981- |
| مواضيع طبية MeSH: | Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use , Sodium-Glucose Transporter 2 Inhibitors*/pharmacology , Magnesium*/metabolism , Homeostasis*/drug effects , Homeostasis*/physiology , Magnesium Deficiency*/drug therapy, Humans ; Animals ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/complications |
| مستخلص: | Magnesium (Mg 2+ ), also known as "the forgotten ion," is the second most abundant intracellular cation and is essential in a broad range of intracellular physiological and biochemical reactions. Its deficiency, hypomagnesemia (Mg 2+ <1.8mg/dL), is a prevalent condition and routinely poses challenges in its management in clinical practice. Sodium/glucose cotransporter 2 (SGLT2) inhibitors have emerged as a new class of drugs with treating hypomagnesemia as their unique extraglycemic benefit. The beneficial effect of SGLT2 inhibitors on magnesium balance in patients with diabetes with or without hypomagnesemia has been noted as a class effect in recent meta-analysis data from randomized clinical trials. Some reports have demonstrated their role in treating refractory hypomagnesemia in patients with or without diabetes. Moreover, studies on animal models have attempted to illustrate the effect of SGLT2 inhibitors on Mg 2+ homeostasis. In this review, we discuss the current evidence and possible pathophysiological mechanisms, and we provide directions for further research. We conclude by suggesting the effect of SGLT2 inhibitors on Mg 2+ homeostasis is a class effect, with certain patients gaining significant benefits. Further studies are needed to examine whether SGLT2 inhibitors can become a desperately needed novel class of medicines in treating hypomagnesemia. (Copyright © 2024 National Kidney Foundation, Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Hypomagnesemia; SGLT2 inhibitors; magnesium; type 2 diabetes |
| المشرفين على المادة: | 0 (Sodium-Glucose Transporter 2 Inhibitors) I38ZP9992A (Magnesium) |
| تواريخ الأحداث: | Date Created: 20240219 Date Completed: 20240423 Latest Revision: 20240808 |
| رمز التحديث: | 20240809 |
| DOI: | 10.1053/j.ajkd.2023.11.006 |
| PMID: | 38372686 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1523-6838 |
|---|---|
| DOI: | 10.1053/j.ajkd.2023.11.006 |